{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000832489","name":"GeoVax Labs, Inc.","summary":"GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine based on Modified Vaccinia Ankara (MVA) vector technology, currently in multiple Phase 2 trials and a BARDA-funded Phase 2b trial. Other programs include Gedeptin for head and neck cancer, GEO-MVA for Mpox/smallpox, and preclinical vaccines for Ebola, Marburg, and Zika.","people":[],"products":[{"name":"GEO-CM04S1","type":"platform","description":"Next-generation COVID-19 vaccine using sMVA vector expressing SARS-CoV-2 spike and nucleocapsid antigens, in multiple Phase 2 trials."},{"name":"Gedeptin","type":"platform","description":"Oncolytic solid tumor gene-directed therapy for advanced head and neck cancers; completed Phase 1/2, Phase 2 planned."},{"name":"GEO-MVA","type":"platform","description":"Vaccine targeting Mpox and smallpox; in regulatory discussions and manufacturing scale-up, clinical evaluation expected in 2025."},{"name":"GEO-EM01-Z","type":"platform","description":"Ebola Zaire vaccine candidate; completed non-human primate studies."},{"name":"GEO-EM01-S","type":"platform","description":"Ebola Sudan vaccine candidate; completed non-human primate studies."},{"name":"GEO-MM01","type":"platform","description":"Marburg vaccine candidate; completed non-human primate studies."},{"name":"GEO-ZM02","type":"platform","description":"Zika vaccine candidate; completed mouse model studies."}],"partnerships":[{"partner_name":"BARDA / Advanced Technology International (ATI-RRPV)","partnership_type":"development","description":"BARDA-funded contract up to $45M to GeoVax for manufacturing and support of GEO-CM04S1 Phase 2b trial under Project NextGen.","start_date":null},{"partner_name":"Allucent","partnership_type":"development","description":"CRO awarded $343M by BARDA to execute the 10,000-participant GEO-CM04S1 Phase 2b clinical trial as part of BARDA's Clinical Studies Network.","start_date":null},{"partner_name":"City of Hope (COH) Medical Center","partnership_type":"licensing","description":"GeoVax licensed exclusive worldwide rights to develop and commercialize GEO-CM04S1 from COH in November 2021.","start_date":null}],"affiliations":[],"origin":{"leaf":"21ff0cf4ada0fc92594e6a79548aa7367681dd3bba60d101216083cb36451ebd","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2d9b96a085d6f402612966344cadb367ce5c0171b564c391ef33e404b12d8112","parent":"a8e849490a87ce4ec423cb397a25c03011ef02e290ea99d51ca0cbe19b846846","source":"0001437749-25-009614","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":183,"hourly_limit":500,"remaining":317,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}